Romoli, M.; Mazzocchetti, P.; D’Alonzo, R.; Siliquini, S.; Rinaldi, V.E.; Verrotti, A.; Calabresi, P.; Costa, C. Valproic acid and epilepsy: From molecular mechanisms to clinical evidences. Curr. Neuropharmacol. 2019, 17, 926–946.
Peterson, G.M.; Naunton, M. Valproate: A simple chemical with so much to offer. J. Clin. Pharm. Ther. 2005, 30, 417–421.
Macritchie, K.A.; Geddes, J.R.; Scott, J.; Haslam, D.R.; Goodwin, G.M. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database Syst. Rev. 2001, 3,
Iannaccone, T.; Sellitto, C.; Manzo, V.; Colucci, F.; Giudice, V.; Stefanelli, B.; Iuliano, A.; Corrivetti, G.; Filippelli, A. Pharmacogenetics of Carbamazepine and Valproate: Focus on Polymorphisms of Drug Metabolizing Enzymes and Transporters. Pharmaceuticals 2021, 14, 204.
Linde, M.; Mulleners, W.M.; Chronicle, E.P.; McCrory, D.C. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database Syst. Rev. 2013, 6.
Guo, A.; Li, J.; Luo, L.; Chen, C.; Lu, Q.; Ke, J.; Feng, X. Valproic acid mitigates spinal nerve ligation-induced neuropathic pain in rats by modulating microglial function and inhibiting neuroinflammatory response. Int. Immunopharmacol. 2021, 92, 107332.
Wang, Y.; Xia, J.; Helfer, B.; Li, C.; Leucht, S. Valproate for schizophrenia. Cochrane Database Syst. Rev. 2016, 11.
Duenas-Gonzalez, A.; Candelaria, M.; Perez-Plascencia, C.; Perez-Cardenas, E.; de la Cruz Hernandez, E.; Herrera, L.A. Valproicacid as epigenetic cancer drug: Preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat. Rev. 2008, 34, 206–222.
Anthony Marson, Girvan Burnside, Richard Appleton, Dave Smith, John Paul Leach, Graeme Sills, Catrin Tudur-Smith, Catrin Plumpton, Dyfrig A Hughes, Paula Williamson, Gus A Baker, Silviya Balabanova, Claire Taylor, Richard Brown, Dan Hindley, Stephen Howell, Melissa Maguire, Rajiv Mohanraj, Philip E Smith, SANAD II collaborators. The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial Lancet. 2021 Apr 10; 397(10282): 1375–1386.
Leppik LE, Bimbaum AK. Epilepsy in elderly. Ann N. Y. Acad. Sci. 2010; 1184, 208-224
Vanadia, E.; Gibson, K.M.; Pearl, P.L.; Trapolino, E.; Mangano, S.; Vanadia, F. Therapeutic efficacy of magnesium valproate in succinic semialdehyde dehydrogenase deficiency. JIMD Rep. 2013, 8, 133–137.
Silva, M.F.; Aires, C.C.; Luis, P.B.; Ruiter, J.P.; IJlst, L.; Duran, M.; Wanders, R.J.; de Almeida, I.T. Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: A review. J.
Inherit. Metab. Dis. 2008, 31, 205–216.
Pal, R.; Singh, K.; Khan, S.A.; Chawla, P.; Kumar, B.; Akhtar, M.J. Reactive metabolites of the anticonvulsant drugs and approaches to minimize the adverse drug reaction. Eur. J. Med. Chem. 2021, 226, 113890
Zhu, M.M.; Li, H.L.; Shi, L.H.; Chen, X.P.; Luo, J.; Zhang, Z.L. The pharmacogenomics of valproic acid. J. Hum. Genet. 2017, 62, 1009–1014
Shnayder NA, Grechkina VV, Khasanova AK, Bochanova EN, Dontceva EA, Petrova MM, Asadullin AR, Shipulin GA, Altynbekov KS, Al-Zamil M, Nasyrova RF. Therapeutic and Toxic Effects of Valproic Acid Metabolites. Metabolites 2023, 13, 134.
Argikar UA, Remmel RP. Effect of Aging on Glucuronidation of Valproic Acid in Human Liver Microsomes and the Role of UDP-Glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Disp. 2009; 37: 229.236
Ebmeyer, J.; Braeuning, A.; Glatt, H.; These, A.; Hessel-Pras, S.; Lampen, A. Human CYP3A4- mediated toxification of the pyrrolizidine alkaloid lasiocarpine. Food Chem. Toxicol. 2019, 130, 79–88
Safdar A, Ismail F. A comprehensive review on pharmacological applications and drug induced toxicity of valproic acid. Saudi Pharmaceutical Journal. 2023; 265-278
Ponchaut, S.; Veitch, K. Valproate and mitochondria. Biochem. Pharmacol. 1993, 46, 199–204.
Souza JDR, Pacheco JK, Rossi JN, de-Paulo BO, Zuardi AW,Guimarães FS, Hallak JEC, Crippa JA, Dos Santos RG. Adverse Effects of Oral Cannabidiol: An Updated Systematic Review of Randomized Controlled Trials (2020–2022). Pharmaceutics. 2022 Dec; 14(12): 2598.
Meseguer ES, Elizalde MU, Borobia AM, Ramírez E. Valproic Acid-Induced Liver Injury: A Case-Control Study from a Prospective Pharmacovigilance Program in a Tertiary Hospital. J. Clin. Med. 2021, 10, 1153.
Nanau, R.M.; Neuman, M.G. Adverse drug reactions induced by valproic acid. Clin. Biochem. 2013, 46, 1323–1338.
Guo, H.-L.; Jing, X.; Sun, J.-Y.; Hu, Y.-H.; Xu, Z.-J.; Ni, M.-M.; Chen, F.; Lu, X.-P.; Qiu, J.-C.; Wang, T. Valproic Acid and the Liver Injury in Patients with Epilepsy: An Update. Curr. Pharm. Des. 2019, 25, 343–351.
Gad AM. Study on the influence of caffeic acid against sodium valproate–induced nephrotoxicity in rats. J Biochem Mol Toxicol. 2018;32:e22175
Anguissola G, Leu D, Simonetti GD, Simonetti BG,Lava SAG, Milani GP, Bianchetti MG, Scoglio M. Kidney tubular injury induced by valproic acid: systematic literature review. Pediatr Nephrol . 2023 Jun;38(6):1725-1731
Karlsson Lind L, Komen J, Wettermark B, et al. Valproic acid utilization among girls and women in Stockholm: impact of regulatory restrictions. Epilepsia Open 2018;3:357-63
La Neve A, Falcicchio G, Trojano M, Boero G. Seizure medication and planned pregnancy: balancing the risks and outcomes. Expert Rev Neurother . 2022 Jul;22(7):527-539.
Vajda FJE, O’Brien TJ, Lander CM, et al. Teratogenesis in repeated pregnancies in antiepileptic drug-treated women. Epilepsia 2013;54(1):181-186
Azzato EM, Chen RA, Wacholder S, et al. Maternal EPHX1 polymorphisms and risk of phenytoininduced congenital malformations. Pharmacogenet Genomics 2010;20:58-63
Jose M, Banerjee M, Mathew A, et al. Pharmacogenetic evaluation of ABCB1, Cyp2C9, Cyp2C19 and methylene tetrahydrofolate reductase polymorphisms in teratogenicity of anti-epileptic drugs in women with epilepsy. Ann Indian Acad Neurol 2014;17:259-66

Epilessia

Articoli

Tossicità indotta dal VPA: Teratogenicità, epatotossicità, nefrotossicità

Ultime risorse

Sanofi Medical Information